Submit Deal

LIMINAL BIOSCIENCES

Summary

Liminal BioSciences is a development-stage biopharmaceutical company focused on discovering and developing novel and distinctive small molecule therapeutics that modulate G protein-coupled receptor pathways.

Deals Overview

Total Deals2

Valued Deals1

Total Value£ 45 M

Avg. Deal Size£ 45 M

Market Context

Senior Management

Kenneth Galbraith
CEO
Bruce Pritchard
CEO
Nicole Rusaw
CFO

Sort

silvermill

financial advisors (1)

1 Shared Deal

1 Opposite

£ 45 M

Total Value

latham & watkins

HQ - New York, United States

legal advisors (1)

1 Shared Deal

1 Opposite

£ 45 M

Total Value

stikeman elliott

HQ - Montreal

legal advisors (2)

2 Shared Deals

2 For

£ 45 M

Total Value

lazard

HQ - New York

financial advisors (1)

1 Shared Deal

1 For

£ 45 M

Total Value

langstaff & co

financial advisors (1)

1 Shared Deal

1 Opposite

n/a

Total Value

torys

HQ - Toronto

legal advisors (1)

1 Shared Deal

1 Opposite

n/a

Total Value

white & case

HQ - New York

legal advisors to financial advisors (1)

1 Shared Deal

1 For

n/a

Total Value

bmo capital markets

HQ - Toronto

financial advisors (1)

1 Shared Deal

1 For

n/a

Total Value

cooley

HQ - Palo Alto

legal advisors (1)

1 Shared Deal

1 For

n/a

Total Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy